Alphatec (ATEC) 10-Q 30 Oct 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 29, 2014
Document And Entity Information [Abstract]	'	'
Entity Registrant Name	'Alphatec Holdings, Inc.	'
Entity Central Index Key	'0001350653	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Document Type	'10-Q	'
Trading Symbol	'ATEC	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	98,193,372

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash	$20,169	$21,345
Restricted cash	2,001	0
Accounts receivable, net	40,053	41,395
Inventories, net	41,986	41,939
Prepaid expenses and other current assets	7,230	7,694
Deferred income tax assets	1,273	1,372
Total current assets	112,712	113,745
Property and equipment, net	26,510	28,030
Goodwill	175,089	183,004
Intangibles, net	32,428	39,064
Other assets	1,863	1,787
Total assets	348,602	365,630
Current liabilities:	'	'
Accounts payable	11,333	10,790
Accrued expenses	34,995	62,996
Deferred revenue	1,142	1,009
Common stock warrant liabilities	10,660	0
Current portion of long-term debt	8,042	4,924
Total current liabilities	66,172	79,719
Long-term debt, less current portion	70,617	49,978
Other long-term liabilities	32,965	38,784
Deferred income tax liabilities	1,925	1,870
Redeemable preferred stock, $0.0001 par value; 20,000 authorized at September 30, 2014 and December 31, 2013; 3,319 shares issued and outstanding at both September 30, 2014 and December 31, 2013	23,603	23,603
Stockholders’ equity:	'	'
Common stock, $0.0001 par value; 200,000 authorized at September 30, 2014 and December 31, 2013; 98,203 and 97,599 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	10	10
Treasury stock, 19 shares	-97	-97
Additional paid-in capital	412,636	403,568
Shareholder note receivable	-5,000	0
Accumulated other comprehensive (loss) income	-5,938	3,877
Accumulated deficit	-248,291	-235,682
Total stockholders’ equity	153,320	171,676
Total liabilities and stockholders’ equity	$348,602	$365,630

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Redeemable preferred stock, par value	$0.00	$0.00
Redeemable preferred stock, shares authorized	20,000,000	20,000,000
Redeemable preferred stock, shares issued	3,319,000	3,319,000
Redeemable preferred stock, shares outstanding	3,319,000	3,319,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	97,961,000	97,599,000
Common stock, shares outstanding	97,961,000	97,599,000
Treasury stock, shares	19,000	19,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenues	$51,013	$50,196	$153,353	$151,659
Cost of revenues	14,272	25,532	46,305	61,303
Amortization of acquired intangible assets	435	432	1,328	1,289
Gross profit	36,306	24,232	105,720	89,067
Operating expenses:	'	'	'	'
Research and development	4,423	3,028	13,138	10,376
In-process research and development	527	0	527	0
Sales and marketing	18,649	18,149	56,545	55,804
General and administrative	10,213	11,443	33,676	34,018
Amortization of acquired intangible assets	742	741	2,257	2,255
Restructuring expenses	20	4,045	706	4,045
Total operating expenses	34,574	37,406	106,849	106,498
Operating income (loss)	1,732	-13,174	-1,129	-17,431
Other income (expense):	'	'	'	'
Interest income	2	2	8	4
Interest expense	-3,875	-1,048	-9,310	-2,670
Other income (expense), net	-928	210	-1,230	-840
Total other income (expense)	-4,801	-836	-10,532	-3,506
Pretax net loss	-3,069	-14,010	-11,661	-20,937
Income tax (benefit) provision	-28	500	948	883
Net loss	($3,041)	($14,510)	($12,609)	($21,820)
Net loss per basic share	'	'	'	'
Net loss per basic share (In dollars per share)	($0.03)	($0.15)	($0.13)	($0.23)
Net loss per diluted share (In dollars per share)	($0.04)	($0.15)	($0.13)	($0.23)
Weighted-average shares used in computing net loss per share:	'	'	'	'
Shares used in calculating basic net loss per share (in shares)	97,391	96,381	97,040	96,046
Shares used in calculating diluted net loss per share (in shares)	98,329	96,381	97,258	96,046

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net loss	($3,041)	($14,510)	($12,609)	($21,820)
Foreign currency translation adjustments	-9,093	4,737	-9,815	1,970
Comprehensive income (loss)	($12,134)	($9,773)	($22,424)	($19,850)

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Operating activities:	'	'
Net loss	($12,609)	($21,820)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:	'	'
Depreciation and amortization	14,006	19,964
Stock-based compensation	3,641	2,832
Interest expense related to amortization of debt discount and debt issuance costs	4,354	285
Provision for doubtful accounts	443	225
Provision for excess and obsolete inventory	2,553	10,842
Deferred income tax expense (benefit)	338	-269
Non-cash in-process research and development expenses	102	0
Other non-cash items	2,655	1,252
Changes in operating assets and liabilities:	'	'
Restricted cash	-2,001	0
Accounts receivable	373	-1,704
Inventories	-3,134	-4,720
Prepaid expenses and other current assets	4,143	1,627
Other assets	-202	57
Accounts payable	-261	-1,921
Accrued expenses and other	-34,684	172
Deferred revenues	-1	-153
Net cash (used in) provided by operating activities	-20,284	6,669
Investing activities:	'	'
Purchases of property and equipment	-7,751	-10,975
Purchase of intangible assets	0	-750
Cash paid for acquisitions	0	-4,000
Cash received from sale of assets	300	0
Net cash used in investing activities	-7,451	-15,725
Financing activities:	'	'
Borrowings under lines of credit	122,066	109,283
Repayments under lines of credit	-115,068	-130,017
Principal payments on capital lease obligations	-605	-1,705
Proceeds from notes payable	24,500	28,000
Principal payments on notes payable	-3,836	0
Net cash provided by financing activities	27,057	5,561
Effect of exchange rate changes on cash	-498	-92
Net decrease in cash	-1,176	-3,587
Cash at beginning of period	21,345	22,241
Cash at end of period	20,169	18,654
Supplemental disclosure of cash flow information:	'	'
Cash paid for interest	4,074	2,759
Cash paid for income taxes	487	804
Purchases of property and equipment in accounts payable	2,217	2,087
Non-cash debt discount	500	0
Initial fair value of warrant liability	10,368	0
Purchase of property and equipment through capital lease	$759	$0

The_Company_and_Basis_of_Prese

The Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
The Company and Basis of Presentation	'
	The Company and Basis of Presentation
	The Company
	Alphatec Holdings, Inc. (“Alphatec”, “Alphatec Holdings” or the “Company”), through its wholly owned subsidiary, Alphatec Spine, Inc. and its subsidiaries (“Alphatec Spine”), designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. In addition to its U.S. operations, the Company also markets its products in over 50 international markets through the distribution channels of Alphatec Spine and its affiliate, Scient’x S.A.S., and its subsidiaries (“Scient’x”), via a direct sales force in Italy and the United Kingdom and via independent distributors in the rest of Europe, the Middle East and Africa. In South America and Latin America, the Company conducts its operations through its Brazilian subsidiary, Cibramed Productos Medicos. In Asia, the Company markets its products through its subsidiary, Alphatec Pacific, Inc. and its subsidiaries (“Alphatec Pacific”), via a direct sales force and independent distributors, and through distributors in other parts of Asia and Australia.
	Basis of Presentation
	The accompanying condensed consolidated balance sheet as of December 31, 2013, which has been derived from audited financial statements, and the unaudited interim condensed consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Certain information and note disclosures normally included in annual audited financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made in this quarterly report on Form 10-Q are adequate to make the information not misleading. The interim unaudited condensed consolidated financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the financial position and results of operations for the periods presented. All such adjustments are of a normal and recurring nature. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2013, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 that was filed with the SEC on March 20, 2014.
	Operating results for the three and nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014, or any other future periods.
	The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. A going concern basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of its liabilities in the normal course of business. Based on the Company’s annual operating plan, management believes that its cash as of September 30, 2014 of $20.2 million combined with anticipated cash flow from operations through September 30, 2015 and other working capital, excluding common stock warrant liabilities, of $37.0 million at September 30, 2014 and the Company's available borrowings under the credit facilities with MidCap Financial, LLC ("MidCap") and Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Special Situations International Master Fund, L.P. (collectively, “Deerfield”), will be sufficient to fund its cash requirements, including the required payments due under the Orthotec litigation settlement (Note 6), through at least September 30, 2015.
	The Company’s amended and restated credit facility (the “Amended Credit Facility”) with MidCap contains financial covenants consisting of a monthly fixed charge coverage ratio, a senior leverage ratio and a total leverage ratio (see Note 5). Based on the Company’s current operating plan, the Company believes that it will be in compliance with the financial covenants of the Amended Credit Facility at least through September 30, 2015. However, there is no assurance that the Company will be able to do so. If the Company is not able to achieve its planned revenue or incurs costs in excess of its forecasts, it may be required to substantially reduce discretionary spending and it could be in default of the Amended Credit Facility. There can be no assurance that the Company could obtain a waiver of such default from MidCap, that the Amended Credit Facility could be successfully renegotiated or that the Company could modify its operations to maintain liquidity. If the Company is unable to obtain any required waiver or amendments, MidCap would have the right to exercise remedies specified in the Amended Credit Facility, including accelerating the repayment of debt obligations. The Company may be forced to seek additional financing, which may include additional debt and/or equity financing or funding through other third party agreements. There can be no assurances that additional financing would be available on acceptable terms or available at all. Furthermore, any equity financing may result in dilution to existing stockholders and any debt financing may involve agreements that include covenants limiting or restricting the Company's ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	The Company’s significant accounting policies are described in Note 2 to its audited consolidated financial statements for the year ended December 31, 2013, which are included in the Company’s Annual Report on Form 10-K that was filed with the SEC on March 20, 2014. Except as discussed below, these accounting policies have not significantly changed during the nine months ended September 30, 2014.
	Restricted Cash
	In March 2014, the Company borrowed and set aside cash for the payment of a portion of the Orthotec litigation settlement (see Note 6) as limited by the terms of the facility agreement that it entered into with Deerfield on March 17, 2014 (see Note 5). The Company classified this cash as restricted, because it may not be used for purposes other than payments of amounts due under the Orthotec litigation settlement agreement.
	In-Process Research and Development
	In-process research and development (“IPR&D”) consists of acquired research and development assets that are not part of an acquisition of a business and were not technologically feasible on the date the Company acquired them and had no alternative future use at that date or IPR&D assets acquired in a business acquisition that are determined to have no alternative future use. The Company expects all acquired IPR&D will reach technological feasibility, but there can be no assurance that commercial viability of these products will ever be achieved. The nature of the efforts to develop the acquired technologies into commercially viable products consists principally of planning, designing, developing and testing products in order to obtain regulatory approvals. If commercial viability were not achieved, the Company would likely look to other alternatives to provide these products. Until the technological feasibility of the acquired research and development assets are established, the Company expenses these costs. The Company expensed $0.5 million as in-process research and development in the three and nine months ended September 30, 2014.
	Fair Value Measurements
	The carrying amount of financial instruments consisting of cash, restricted cash, trade accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses, accrued compensation and current portion of long-term debt included in the Company’s consolidated financial statements are reasonable estimates of fair value due to their short maturities. Based on the borrowing rates currently available to the Company for loans with similar terms, management believes the fair value of long-term debt approximates its carrying value.
	Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level 1:	Observable inputs such as quoted prices in active markets;
	Level 2:	Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3:	Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	The Company does not maintain any financial instruments that are considered to be Level 1 or Level 2 instruments as of September 30, 2014 or December 31, 2013. The Company classifies its common stock warrant liabilities within Level 3 of the fair value hierarchy because they are valued using valuation models with significant unobservable inputs. The following table provides a reconciliation of liabilities measured at fair value using significant unobservable inputs (Level 3) for the nine months ended September 30, 2014 (in thousands):
		Common Stock Warrant Liabilities
	Balance at December 31, 2013	$	—
	Issuance	10,368
	Changes in fair value	292
	Balance at September 30, 2014	$	10,660
	Common stock warrant liabilities are measured at fair value using the Black-Scholes option pricing valuation model. The assumptions used in the Black-Scholes option pricing valuation model for the common stock warrant liabilities were: (a) a risk-free interest rate based on the rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the remaining contractual term of the warrants; (b) an assumed dividend yield of zero based on the Company’s expectation that it will not pay dividends in the foreseeable future; (c) an expected term based on the remaining contractual term of the warrants; and (d) an expected volatility based upon the Company's historical volatility over the remaining contractual term of the warrants. The significant unobservable input used in measuring the fair value of the common stock warrant liabilities associated with the Deerfield Facility Agreement (defined below) is the expected volatility. Significant increases in volatility would result in a higher fair value measurement. The increase in the fair value of the common stock warrant liabilities as of September 30, 2014 was primarily driven by the increase in the Company's stock price at September 30, 2014 as compared to the Company's stock price on March 17, 2014, the date the common stock warrants were issued.
	Warrants to Purchase Common Stock
	Common stock warrants that contain compliance covenants and cash payment obligations are classified as common stock warrant liabilities on the consolidated balance sheet. The Company records the warrant liability at fair value and adjusts the carrying value of these common stock warrants to their estimated fair value at each reporting date with the increases or decreases in the fair value of such warrants at each reporting date recorded as other income (expense) in the consolidated statement of operations.
	Recent Accounting Pronouncements
	In March 2013, the Financial Accounting Standards Board (“FASB”) issued guidance on a parent company’s accounting for the cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. This new guidance requires that the parent release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. The amendments became effective for the Company beginning January 1, 2014. The Company adopted this guidance and the adoption did not have any impact on the Company's financial statements.
	In April 2014, the FASB issued new guidance related to reporting discontinued operations. This new standard raises the threshold for a disposal to qualify as a discontinued operation and requires new disclosures of both discontinued operations and certain other disposals that do not meet the definition of a discontinued operation. The new standard is effective for fiscal years beginning on or after December 15, 2014. The Company is evaluating the impact, if any, of adopting this new accounting standard on its financial statements.
	In May 2014, the FASB issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for the Company beginning January 1, 2017 and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is evaluating the impact of adopting this new accounting standard on its financial statements.
	In August 2014, the FASB issued guidance related to disclosures of uncertainties about an entity’s ability to continue as a going concern. The guidance requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued. Management will be required to make this evaluation for both annual and interim reporting periods and will have to make certain disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the entity’s ability to continue as a going concern. Substantial doubt exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued. The guidance is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter 2017, with early adoption permitted. The Company is currently evaluating the impact of this guidance and expects to adopt the standard for the annual reporting period ended December 31, 2016.

Select_Balance_Sheet_Details

Select Balance Sheet Details	9 Months Ended
	Sep. 30, 2014
Balance Sheet Related Disclosures [Abstract]	'
Select Balance Sheet Details	'
	Select Balance Sheet Details
	Accounts Receivable, net
	Accounts receivable, net consist of the following (in thousands):
		September 30, 2014				December 31, 2013
	Accounts receivable	$	41,062			$	42,443
	Allowance for doubtful accounts	(1,009		)		(1,048		)
	Accounts receivable, net	$	40,053			$	41,395
	Inventories, net
	Inventories, net consist of the following (in thousands):
		September 30, 2014										December 31, 2013
		Gross				Reserve for				Net		Gross		Reserve for			Net
						excess and								excess and
						obsolete								obsolete
	Raw materials	$	4,526			$	—			$	4,526	$	4,375	$	—		$	4,375
	Work-in-process	1,017				—				1,017		531		—			531
	Finished goods	57,317				(20,874		)		36,443		60,979		(23,946		)	37,033
	Inventories	$	62,860			$	(20,874	)		$	41,986	$	65,885	$	(23,946	)	$	41,939
	Property and Equipment, net
	Property and equipment, net consist of the following (in thousands except as indicated):
		Useful lives		September 30, 2014				December 31, 2013
		(in years)
	Surgical instruments	4		$	63,019			$	62,636
	Machinery and equipment	7		15,461				14,692
	Computer equipment	3		3,193				3,357
	Office furniture and equipment	5		3,823				3,703
	Leasehold improvements	various		3,719				4,161
	Building	39		72				52
	Land	n/a		10				10
	Construction in progress	n/a		1,016				1,228
				90,313				89,839
	Less accumulated depreciation and amortization			(63,803		)		(61,809		)
	Property and equipment, net			$	26,510			$	28,030
	Total depreciation expense was $2.9 million and $3.7 million for the three months ended September 30, 2014 and 2013, respectively. Total depreciation expense was $9.2 million and $10.9 million for the nine months ended September 30, 2014 and 2013, respectively. At September 30, 2014, assets recorded under capital leases of $3.2 million were included in the machinery and equipment balance. At December 31, 2013, assets recorded under capital leases of $1.8 million were included in the machinery and equipment balance and $0.6 million were included in the construction in progress balance. Amortization of assets under capital leases was included in depreciation expense.
	Intangible Assets, net
	Intangible assets, net consist of the following (in thousands except for useful lives):
		Useful lives		September 30, 2014				December 31, 2013
		(in years)
	Developed product technology	8-Mar		$	22,880			$	23,633
	Distribution rights	3		2,270				2,343
	Intellectual property	5		1,004				1,004
	License agreements	7-Jan		16,716				17,686
	Core technology	10		4,740				5,137
	Trademarks and trade names	9-Mar		3,674				3,920
	Customer-related	15-Dec		21,026				22,161
	Distribution network	12-Oct		4,027				4,027
	Physician education programs	10		2,916				3,160
	Supply agreement	10		225				225
				79,478				83,296
	Less accumulated amortization			(47,050		)		(44,232		)
	Intangible assets, net			$	32,428			$	39,064
	Total amortization expense was $1.6 million and $3.7 million for the three months ended September 30, 2014 and 2013, respectively. Total amortization expense was $4.8 million and $9.1 million for the nine months ended September 30, 2014 and 2013, respectively.
	Future amortization expense related to intangible assets as of September 30, 2014 is as follows (in thousands):
	Year Ending December 31,
	Remainder of 2014	$	1,493
	2015	5,792
	2016	5,281
	2017	4,984
	2018	3,127
	Thereafter	11,751
		$	32,428
	Accrued Expenses
	Accrued expenses consist of the following (in thousands):
		September 30, 2014				December 31, 2013
Legal	$	570			$	2,139
Accounting	949				928
Severance	459				297
Restructuring	730				9,170
Sales milestones	96				1,828
Accrued taxes	811				1,120
Deferred rent	884				1,163
Royalties	2,443				2,347
Commissions	5,275				6,180
Payroll and related	8,013				9,369
Litigation settlements	8,386				22,600
Accrued interest	887				416
Other	5,492				5,439
Total accrued expenses	$	34,995			$	62,996
Goodwill
The changes in the carrying amount of goodwill from December 31, 2013 through September 30, 2014 are as follows (in thousands):
Balance at December 31, 2013	$	183,004
Effect of foreign exchange rate on goodwill	(7,915		)
Balance at September 30, 2014	$	175,089

License_and_Consulting_Agreeme

License and Consulting Agreements	9 Months Ended
	Sep. 30, 2014
Contractors [Abstract]	'
License and Consulting Agreements	'
	License and Consulting Agreements
	The Company’s license and consulting agreements are described in Note 5 to its audited consolidated financial statements for the year ended December 31, 2013, which are included in its Annual Report on Form 10-K which was filed with the SEC on March 20, 2014.
	OsseoFix Spinal Fracture Reduction License Agreement
	On April 16, 2009, the Company and Stout Medical Group LP (“Stout”) amended the license agreement that the parties had entered into in September 2007 (the “License Amendment”) that provides the Company with a worldwide license to develop and commercialize Stout’s proprietary intellectual property related to a treatment for vertebral compression fractures. The effective date of the License Amendment is March 31, 2009. Under the License Amendment, the timing of the minimum royalty payments has been adjusted and Stout’s ability to terminate the License Amendment was revised. Under the original license agreement, the Company’s minimum royalty obligation began in the year ending December 31, 2009 and there are milestones due upon attainment of sales volumes. Pursuant to the License Amendment, the minimum royalty obligation is suspended until a licensed product obtains regulatory approval from the United States Food and Drug Administration (the “FDA”). In addition, under the terms of the License Amendment, Stout has the ability to terminate the License Amendment if the Company is not using commercially reasonable efforts to obtain regulatory approval to market and sell a licensed product; provided that the Company has the right to delay such termination in exchange for making certain payments to Stout. If, during the time period when such payments are made, the Company were to make a regulatory filing for the marketing and sale of a licensed product, such termination will be null and void. Pursuant to the License Amendment, Stout is entitled to retain all up-front payments that had been previously paid to it. The other material terms of the license agreement were not changed in the License Amendment.
	In August 2014, the Company entered a third amendment (the “Third Amendment”) to the License Agreement. Pursuant to the Third Amendment: (i) the royalty rate paid by the Company for the net sales of licensed products is a fixed amount per quarter through December 31, 2016; (ii) the royalty rate starting in 2017 will be increased from 7.0% to 8.5%; (ii) starting in 2017, the minimum royalty obligation is $0.2 million per year, with such minimum royalty obligation being further reduced stating in 2018; (iii) the territory is amended so that the United States is removed from the territory in which the Company can sell and market licensed products; (iv) all obligations of the Company to purse a clinical trial in the United States are deleted; and (v) all milestone payments based on the achievement of certain sales milestones are deleted. In connection with this amendment the Company reversed the $1.7 million accrual it had recorded for the sales milestone payment into cost of goods sold for the three and nine months ended September 30, 2014.
	Asset Purchase Agreement
	In July 2014, the Company entered into an asset purchase and product development services agreement (the "Asset Agreement") whereby the Company purchased rights to the conceptual design for an intervertebral implant device. The financial terms of the Agreement include payments in cash and the Company's common stock upon achievement of various milestones. The Company treated this arrangement as an asset acquisition. In the three months ended September 30, 2014, the Company made cash payments totaling $0.2 million and issued 72,992 shares of the Company's common stock valued at $0.1 million. The Company recognized the cash and stock payments of $0.3 million as in-process research and development expense in the three and nine months ended September 30, 2014.

Debt

Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	Debt
	MidCap Facility Agreement
	On August 30, 2013, the Company entered into an Amended and Restated Credit, Security and Guaranty Agreement (the "Amended Credit Facility") with MidCap. The Amended Credit Facility amended and restated the prior credit facility that the Company had with MidCap (the "Credit Facility").
	Pursuant to the Amended Credit Facility, the Company increased the borrowing limit from $50 million to $73 million. The Company also extended the maturity to August 2016. The Amended Credit Facility consists of a $33 million term loan, $28 million of which was drawn at closing and the remaining $5 million of which was drawn in April 2014, and a revolving line of credit with a maximum borrowing base of $40 million, of which $31.8 million was outstanding at September 30, 2014. The Company used the term loan proceeds of $28 million drawn at closing to repay a portion of the outstanding balance on the prior revolving line of credit.
	The term loan interest rate is priced at the London Interbank Offered Rate ( "LIBOR") plus 8.0%, subject to a 9.5% floor, and the revolving line of credit interest rate remains priced at LIBOR plus 6.0%, reset monthly. At September 30, 2014, the revolving line of credit carried an interest rate of 6.2% and the term loan carries an interest rate of 9.5%. The borrowing base is determined, from time to time, based on the value of domestic eligible accounts receivable and domestic eligible inventory. As collateral for the Amended Credit Facility, the Company granted MidCap a security interest in substantially all of its assets, including all accounts receivable and all securities evidencing its interests in its subsidiaries. In addition to monthly payments of interest, monthly repayments of $0.3 million of the principal for the term loan were made beginning in October 2013, increasing to $0.5 million beginning in October 2014, and are due through maturity, with the remaining principal due upon maturity.
	In connection with the execution of the Amended Credit Facility, the Company incurred an additional $0.4 million in costs that were capitalized as debt issuance costs within the unaudited consolidated balance sheet as of September 30, 2013. At September 30, 2014, $0.5 million remains as unamortized debt issuance costs related to the prior and Amended Credit Facility within the unaudited consolidated balance sheet, which will be amortized over the remaining term of the Amended Credit Facility.
	The Amended Credit Facility includes traditional lending and reporting covenants including a fixed charge coverage ratio, a senior leverage ratio and a total leverage ratio to be maintained by the Company. The Amended Credit Facility also includes several potential events of default, such as payment default and insolvency conditions, which could cause interest to be charged at a rate which is up to five percentage points above the rate effective immediately before the event of default or result in MidCap’s right to declare all outstanding obligations immediately due and payable.
	In January 2013, the Company entered into a limited waiver and limited consent agreement with MidCap (the “Waiver”). Under the Waiver, MidCap gave the Company its consent to waive certain provisions of the Credit Facility in connection with the acquisition of the assets of Phygen, LLC ("Phygen") and related to the maintenance of cash balances in the U.S. In February 2013, the Company and MidCap entered into a first amendment to the Credit Facility (the "First Amendment to the Credit Facility”). The First Amendment to the Credit Facility allowed the Company to exclude payments related to the Phygen acquisition and the settlement agreement with Cross Medical Products, LLC (“Cross”) from calculation of the fixed charge coverage ratio and the senior leverage ratio. In conjunction with the First Amendment to the Credit Facility, the Company paid MidCap a fee of $0.1 million. In July 2013, the Company entered into a second limited waiver and limited consent agreement with MidCap (the “Second Waiver”). Under the Second Waiver, MidCap gave the Company its consent to waive certain provisions of the Credit Facility related to the maintenance of cash balances in the U.S. for past periods through September 30, 2013. On August 30, 2013, the Company entered into the Amended Credit Agreement with MidCap.
	On March 17, 2014, the Company entered into a first amendment to the Amended Credit Facility with MidCap (the "First Amendment to the Amended Credit Facility"). Under the First Amendment to the Amended Credit Facility, MidCap gave the Company its consent to enter into the Facility Agreement (defined below) and make settlement payments in connection with the Orthotec litigation. The First Amendment to the Amended Credit Facility also added a total leverage ratio financial covenant. The Company was in compliance with all of the covenants of the Amended Credit Facility as of September 30, 2014.
	Deerfield Facility Agreement
	On March 17, 2014, the Company entered into a facility agreement (the “Facility Agreement”) with Deerfield, pursuant to which Deerfield agreed to loan the Company up to $50 million, subject to the terms and conditions set forth in the Facility Agreement. Under the terms of the Facility Agreement, the Company has the option, but is not required, upon certain conditions to draw the entire amount available under the Facility Agreement, at any time until January 30, 2015 (the “Draw Period”), provided that the initial draw be used for a portion of the payments made in connection with the Orthotec settlement described in Note 6 below. Following such initial draw down, the Company may draw down additional amounts under the Facility Agreement up to an aggregate $15 million for working capital or general corporate purposes in $2.5 million increments until the end of the Draw Period. The Company has agreed to pay Deerfield, upon each disbursement of funds under the Facility Agreement, a transaction fee equal to 2.5% of the principal amount of the funds disbursed. Amounts borrowed under the Facility Agreement bear interest at a rate of 8.75% per annum and are payable on the third, fourth and fifth anniversary date of the first amount borrowed under the Facility Agreement, with the final payment due on March 20, 2019.
	The Facility Agreement also contains various representations and warranties, and affirmative and negative covenants, customary for financings of this type, including restrictions on the ability of the Company and its subsidiaries to incur additional indebtedness or liens on its assets, except as permitted under the Facility Agreement. As security for our repayment of our obligations under the Facility Agreement, we granted to Deerfield a security interest in substantially all of our property and interests in property, which is subordinated to the security interest granted under the Amended Credit Facility.
	In connection with the execution of the Facility Agreement on March 17, 2014, the Company issued to Deerfield warrants to purchase an aggregate of 6,250,000 shares of the Company’s common stock (the “Initial Warrants”) (See Note 8). Additionally, each disbursement borrowing under the Facility Agreement shall be accompanied by the issuance to Deerfield of warrants to purchase up to 10,000,000 shares of the Company’s common stock, in proportion to the amount of draw compared to the total $50 million facility (the "Draw Warrants") (See Note 8).
	On March 20, 2014, the Company made an initial draw of $20 million under the Facility Agreement and received net proceeds of $19.5 million to fund the portion of the Orthotec settlement payment obligations that are due in 2014. The $0.5 million transaction fee is recorded as a debt discount and is being amortized over the term of the draw, which ends March 20, 2019. In connection with this borrowing, the Company issued 4,000,000 Draw Warrants, which were valued at $4.7 million and recorded as a debt discount and is being amortized over the term of the $20 million draw. Additionally, $2.3 million of the value of the Initial Warrants was reclassified as a debt discount and is being amortized through interest expense over the term of the debt using the effective interest method. Orthotec settlement payments of $17.5 million were made in the nine months ending September 30, 2014, leaving remaining proceeds of $2.0 million, which were classified as restricted cash, as their use is limited under the terms of the Facility Agreement for the payments of amounts due under the Orthotec litigation settlement agreement. Additionally, a payment of $1.1 million was made on October 1, 2014. The amounts borrowed under the Facility Agreement are due in three equal annual payments beginning March 20, 2017.
	Principal payments on debt are as follows as of September 30, 2014 (in thousands):
	Year Ending December 31,
	Remainder of 2014	$	2,018
	2015	6,869
	2016	54,894
	2017	6,667
	2018	6,667
	Thereafter	6,666
	Total	83,781
	Add: capital lease principal payments	1,491
	Less: debt discount	(6,613		)
	Total	78,659
	Less: current portion of long-term debt	(8,042		)
	Long-term debt, net of current portion	$	70,617

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Leases
	The Company leases certain equipment under capital leases which expire on various dates through June 2017. The leases bear interest at rates ranging from 6.6% to 9.6% per annum, are generally due in monthly principal and interest installments and are collateralized by the related equipment. The Company also leases its buildings and certain equipment and vehicles under operating leases which expire on various dates through January 2019. Future minimum annual lease payments under such leases are as follows as of September 30, 2014 (in thousands):
	Year Ending December 31,	Operating		Capital
	Remainder of 2014	$	877	$	181
	2015	3,228		662
	2016	1,827		623
	2017	377		183
	2018	68		—
	Thereafter	4		—
		$	6,381	1,649
	Less: amount representing interest			(158		)
	Present value of minimum lease payments			1,491
	Current portion of capital leases			(586		)
	Capital leases, less current portion			$	905
	Rent expense under operating leases for the three months ended September 30, 2014 and 2013 was $0.8 million and $0.9 million, respectively. Rent expense under operating leases for the nine months ended September 30, 2014 and 2013 was $2.6 million and $2.9 million, respectively.
	Litigation
	The Company previously reported that on March 15, 2014, the Company had entered into a binding term sheet (the "Binding Term Sheet") to resolve the Orthotec, LLC v. Surgiview, S.A.S, et al. matter in the Superior Court of California, Los Angeles County and related litigation matters (the "Orthotec Settlement"). Both the Orthotec litigation matter and the Orthotec Settlement have been previously reported. Pursuant to the terms contained in the Binding Term Sheet, the Company agreed to pay Orthotec, LLC $49 million in cash, including initial cash payments totaling $1.75 million, which the Company previously paid in March 2014, and an additional lump sum payment of $15.75 million, which the Company previously paid in June 2014. The Company agreed to pay the remaining $31.5 million in 28 quarterly installments of $1.1 million and then one additional quarterly installment of $700,000, commencing October 1, 2014. The Company has the right to prepay the amounts due without penalty. In addition, the unpaid balance of the amounts due will accrue interest at the rate of 7% per year beginning May 15, 2014 until the amounts due are paid in full. The accrued but unpaid interest will be paid in quarterly installments of $1.1 million (or the full amount of the accrued but unpaid interest if less than $1.1 million) following the full payment of the $31.5 million in quarterly installments described above. No interest will accrue on the accrued interest. The Binding Term Sheet provided for mutual releases of all claims in the Orthotec, LLC v. Surgiview, S.A.S, et al. matter in the Superior court of California, Los Angeles County and all other related litigation matters involving the Company, its directors and affiliates.
	On September 26, 2014, the Company entered into a Settlement and Release Agreement, dated as of August 13, 2014, by and among the Company and its direct subsidiaries, including Alphatec Spine, Inc., Alphatec Holdings International C.V., Scient'x S.A.S. and Surgiview S.A.S.; HealthpointCapital, LLC, HealthpointCapital Partners, L.P., HealthpointCapital Partners II, L.P., John H. Foster and Mortimer Berkowitz III; and Orthotec, LLC and Patrick Bertranou, (the "Settlement Agreement"). The Settlement Agreement contains substantially the same business terms as the Binding Term Sheet set forth above, and supersedes the Binding Term Sheet.
	On August 10, 2010, a purported securities class action complaint was filed in the United States District Court for the Southern District of California on behalf of all persons who purchased the Company's common stock between December 19, 2009 and August 5, 2010 against the Company and certain of its directors and officers alleging violations of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b-5 promulgated thereunder. On February 17, 2011, an amended complaint was filed against the Company and certain of its directors and officers adding alleged violations of the Securities Act of 1933 (the "Securities Act"), as amended. HealthpointCapital, Jefferies & Company, Inc., Canaccord Adams, Inc., Cowen and Company, Inc., and Lazard Capital Markets LLC are also defendants in this action. The complaint alleges that the defendants made false or misleading statements and failed to disclose material facts about the Company’s business, financial condition, operations and prospects, particularly relating to the Scient’x transaction and the Company's financial guidance following the closing of the acquisition. The complaint seeks unspecified monetary damages, attorneys’ fees, and other unspecified relief. The Company filed a motion to dismiss the amended complaint on April 18, 2011. The district court granted the motion to dismiss with leave to amend on March 22, 2012. On April 19, 2012, the lead plaintiff filed a Second Amended Complaint alleging violations of Sections 10(b) and 20(a) of the Exchange Act and violations of Section 11, 12(a)(2), and 15 of the Securities Act against the same named defendants. On May 3, 2012, the Company filed a motion to dismiss the Second Amended Complaint. The district court granted that motion without leave to amend and entered final judgment in the Company’s favor on March 28, 2013. On April 17, 2013, the lead plaintiff filed a notice of appeal to the United States Court of Appeals for the Ninth Circuit. The appeal has been fully briefed. The Company believes that the claims are without merit and it intends to vigorously defend itself against this complaint. However, the outcome of the litigation cannot be predicted at this time and any outcome that is adverse to the Company, regardless of who the defendant is, could have a significant adverse effect on its financial condition and results of operations.
	On August 25, 2010, an alleged shareholder of the Company filed a derivative lawsuit in the Superior Court of California, San Diego County, purporting to assert claims on behalf of the Company against all of its directors and certain of its officers and HealthpointCapital. Following the filing of this complaint, similar complaints were filed in the same court and in the U.S. District Court for the Southern District of California against the same defendants containing similar allegations. The complaint filed in federal court was dismissed by the plaintiff without prejudice in July 2011. The state court complaints were consolidated into a single action and the Company was named as a nominal defendant in the consolidated action. Each complaint alleges that the Company’s directors and certain of its officers breached their fiduciary duties to the Company related to the Scient’x transaction, and allegedly made false statements that led to unjust enrichment of HealthpointCapital and certain of the Company’s directors. The complaints seek unspecified monetary damages and an order directing the Company to adopt certain measures purportedly designed to improve its corporate governance and internal procedures. On January 8, 2014, the parties reached an agreement in principle to resolve all claims in exchange for corporate governance reforms and payment of attorneys’ fees in the amount of $5.25 million, to be paid by the Company’s and HeathpointCapital’s respective insurance carriers. The settlement was approved in August 2014.
	At September 30, 2014, the probable outcome of any of the aforementioned litigation matters that have not reached a settlement cannot be determined nor can the Company estimate a range of potential loss. Accordingly, in accordance with the authoritative guidance on the evaluation of contingencies, the Company has not recorded an accrual related to any litigation matters that have not reached a settlement. The Company is and may become involved in various other legal proceedings arising from its business activities. While management does not believe the ultimate disposition of the above matters that have not yet been settled will have a material adverse impact on the Company’s consolidated results of operations, cash flows or financial position, litigation is inherently unpredictable, and depending on the nature and timing of these proceedings, an unfavorable resolution could materially affect the Company’s future consolidated results of operations, cash flows or financial position in a particular period.
	Royalties
	The Company has entered into various intellectual property agreements requiring the payment of royalties based on the sale of products that utilize such intellectual property. These royalties primarily relate to products sold by Alphatec Spine and are calculated either as a percentage of net sales or in one instance on a per-unit sold basis. Royalties are included on the accompanying condensed consolidated statement of operations as a component of cost of revenues.

Net_Loss_Per_Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	Net Loss Per Share
	Basic earnings per share (“EPS”) is calculated by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted EPS is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding for the period and the weighted average number of dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, common stock subject to repurchase by the Company, options and warrants are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share when their effect is dilutive (in thousands, except per share data):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2014				2013			2014			2013
	Numerator:
	Net loss for basic earnings per share	$	(3,041	)		$	(14,510	)	$	(12,609	)	$	(21,820	)
	Decrease in fair value of warrants	(513		)		—			(520		)	—
	Diluted net loss applicable to common stockholders	$	(3,554	)		$	(14,510	)	$	(13,129	)	$	(21,820	)
	Denominator:
	Weighted average common shares outstanding	98,126				97,318			97,864			96,940
	Weighted average unvested common shares subject to repurchase	(735		)		(937		)	(824		)	(894		)
	Weighted average common shares outstanding—basic	97,391				96,381			97,040			96,046
	Effect of dilutive securities:
	Conversion of preferred stock	—				—			—			—
	Options	—				—			—			—
	Warrants	938				—			218			—
	Weighted average common shares outstanding—diluted	98,329				96,381			97,258			96,046
	Net loss per share:
	Basic	$	(0.03	)		$	(0.15	)	$	(0.13	)	$	(0.23	)
	Diluted	$	(0.04	)		$	(0.15	)	$	(0.13	)	$	(0.23	)
	The anti-dilutive securities not included in diluted net loss per share were as follows (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014		2013
	Options to purchase common stock	6,904			2,383			7,199		4,355
	Unvested restricted share awards	735			937			824		894
	Warrants to purchase common stock	594			594			6,844		594
	Total	8,233			3,914			14,867		5,843

Equity_Transactions

Equity Transactions	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Equity Transactions	'
	Equity Transactions
	Warrants
	In connection with the execution of the Facility Agreement, on March 17, 2014, the Company issued to Deerfield warrants to purchase an aggregate of 6,250,000 shares of the Company’s common stock immediately exercisable at an exercise price equal to $1.39 (the “Initial Warrants”) expiring on March 17, 2020. The number of shares of common stock into which the Initial Warrants are exercisable and the exercise price will be adjusted to reflect any stock splits, payment of stock dividends, recapitalizations, reclassifications or other similar adjustments in the number of outstanding shares of the Company’s common stock. The warrants have the same dividend rights to the same extent as if the warrants had been exercised for shares of common stock.
	Each disbursement borrowing under the Facility Agreement shall be accompanied by the issuance to Deerfield of additional warrants to purchase up to an aggregate of 10,000,000 shares of the Company’s common stock, at an exercise price equal to the lesser of the Initial Warrant exercise price or the average daily volume weighted average price per share of the Company’s common stock for the 15 days following the request for borrowing (the “Draw Warrants”). The number of Draw Warrants issued for each draw will be in proportion to the amount of draw compared to the total $50 million facility.
	The Initial Warrants were valued on March 17, 2014 using a Black-Scholes option pricing model that resulted in a value of $5.7 million, which was recorded as a current liability with an offset to a deferred charge asset and will be amortized on a straight line basis through interest expense over the term of the Facility Agreement commitment period ending January 30, 2015. To the extent the Company draws on the $50 million Facility Agreement, a proportionate amount of the unamortized current deferred charge will be reclassified as debt discount and amortized through interest expense over the term of the debt using the effective interest method.
	On March 20, 2014, the Company made an initial draw of $20 million under the Facility Agreement and received net proceeds of $19.5 million to fund the portion of the Orthotec settlement payment obligations that are due in 2014. In connection with this borrowing, the Company issued Draw Warrants to purchase 4,000,000 shares of common stock at an exercise price of $1.39. The Draw Warrants were valued at $4.7 million using the Black-Scholes option pricing model, which was recorded as a current liability with an offset to debt discount. In connection with the $20 million draw, $2.3 million of the deferred charge recorded upon the issuance of the Initial Warrants was reclassified as a debt discount.
	As of September 30, 2014, the 10,250,000 outstanding Initial Warrants and Draw Warrants were revalued to their fair value with a charge to other income (expense) of $0.5 million and ($0.3 million) for the three and nine months ended September 30, 2014. The warrant liability of $10.7 million is recorded as common stock warrant liabilities within current liabilities on the condensed consolidated balance sheet as of September 30, 2014.
	At September 30, 2014, our outstanding warrants were valued using the Black-Scholes option pricing model. This is a Level 3 measurement using the following assumptions:
		September 30, 2014
	Risk-free interest rate	1.9	%
	Dividend yield	—	%
	Expected volatility	63	%
	Expected life (years)	5.5

Stock_Benefit_Plans_and_StockB

Stock Benefit Plans and Stock-Based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Benefit Plans and Stock-Based Compensation	'
	Stock Benefit Plans and Stock-Based Compensation
	In July 2014, the Company granted 932,000 performance-based restricted stock units ("PSUs") to certain employees under its 2005 Employee, Director and Consultant Stock Plan (the "2005 Plan"). The PSUs vest based upon the Company's achievement of certain performance goals over the period from July 1, 2014 through December 31, 2016. The number of PSUs that may vest varies between 0%-200% based on the achievement of such goals. The PSUs were valued at $1.42 per share based on the closing price of the Company's common stock on the date of grant. For purposes of measuring compensation expense, the amount of PSUs ultimately expected to vest is estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. The recognition of compensation expense associated with PSUs requires judgment in assessing the probability of meeting the performance goals, as well as defined criteria for assessing achievement of the performance-related goals.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	To calculate its interim tax provision, at the end of each interim period the Company estimates the annual effective tax rate and applies that to its ordinary quarterly earnings. In addition, the effect of changes in enacted tax laws or rates or tax status is recognized in the interim period in which the change occurs. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in foreign jurisdictions, permanent and temporary differences between book and tax amounts, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, additional information is obtained or as the tax environment changes.
	The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision. The Company’s unrecognized tax benefits decreased less than $0.1 million during the nine months ended September 30, 2014. The decrease in unrecognized tax benefits during the nine months ended September 30, 2014 was primarily related to foreign currency fluctuations and changes in prior year uncertain tax positions within the Company's foreign subsidiaries, partially offset by an increase related to state research credits and uncertain tax positions within the Company’s foreign subsidiaries. The unrecognized tax benefits at September 30, 2014 and December 31, 2013 were $7.8 million. With the facts and circumstances currently available to the Company, it is reasonably possible that the amount that could reverse over the next 12 months is insignificant. Additionally, the French restructuring (see Note 11) may result in limitations on the Company’s ability to utilize its French net operating loss carryforwards to offset future taxable income.
	The income tax provision consists primarily of income tax provisions related to state income taxes, the tax effect of changes in deferred tax liabilities associated with tax deductible goodwill and operations in other foreign jurisdictions where the Company operates.
	The Company is not currently under examination by the Internal Revenue Service, or by foreign, state or local tax authorities.

Segment_and_Geographical_Infor

Segment and Geographical Information	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment and Geographical Information	'
	Segment and Geographical Information
	Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has one operating and one reportable business segment.
	During the three and nine months ended September 30, 2014 and 2013, the Company operated in two geographic regions, the U.S. and International, which consists of locations outside of the U.S. In the International geographic region, sales in Japan for the three and nine months ended September 30, 2014 totaled $8.5 million and $23.8 million, respectively, which represented greater than 10 percent of the Company’s consolidated revenues. In the International geographic region, sales in Japan for the three and nine months ended September 30, 2013 totaled $7.3 million and $20.8 million which represented greater than 10 percent of the Company’s consolidated revenues.
	Revenues attributed to the geographic location of the customer were as follows (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	United States	$	34,808	$	33,696	$	101,376	$	99,249
	International	16,205		16,500		51,977		52,410
	Total consolidated revenues	$	51,013	$	50,196	$	153,353	$	151,659
	Total assets by region were as follows (in thousands):
		September 30,		December 31,
		2014		2013
	United States	$	200,012	$	196,383
	International	148,590		169,247
	Total consolidated assets	$	348,602	$	365,630

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring	'
	Restructuring
	On September 16, 2013, the Company announced that Scient'x began a process to significantly restructure its business operations in France in an effort to improve operating efficiencies and rationalize its cost structure. The restructuring included a reduction in Scient'x's workforce and closing of the manufacturing facilities in France. The Company has recorded total costs of $10.4 million to date associated with this restructuring, which includes employee severance, social plan benefits and related taxes, facility closing costs, manufacturing transfer costs, and contract termination costs. In accordance with ASC Topic 420, Accounting for Costs Associated with Exit or Disposal Activities, and ASC Topic 712, Non Retirement Postemployment Benefits, the Company has recorded a restructuring charge accrual in accrued expenses of $0.7 million within the condensed consolidated balance sheet as of September 30, 2014. Additionally, the Company has recorded restructuring expense of $0.7 million within the condensed consolidated statement of operations for the nine months ending September 30, 2014. The Company has substantially completed the activities associated with the restructuring as of September 30, 2014, and a substantial portion has been paid.
	Below is a table of the movement (in thousands):
		Accrued Balance at		Expensed		Paid and			Accrued Balance at		Total Costs
		31-Dec-13		September 30, 2014		Other			30-Sep-14		Incurred
	Social plan costs	$	9,170	$	197	$	(8,637	)	$	730	$	9,450
	Other restructuring costs	—		509		(509		)	—		921
	Total	$	9,170	$	706	$	(9,146	)	$	730	$	10,371

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Related Party Transactions
	For the nine months ended September 30, 2014, the Company incurred expenses of $0.2 million and had a liability of $0.2 million payable to HealthpointCapital, LLC for travel and administrative expenses.
	The Company has entered into indemnification agreements with certain of its directors which are named defendants in the New York Orthotec matter (see Note 6 – Commitments and Contingencies – Litigation). The indemnification agreements require the Company to indemnify these individuals to the fullest extent permitted by applicable law and to advance expenses incurred by them in connection with any proceeding against them with respect to which they may be entitled to indemnification by the Company. For the nine months ended September 30, 2014 and 2013, the Company incurred legal expenses of less than $0.1 million and $1.3 million, respectively, in connection with the Company’s indemnification obligations to two former directors of Scient'x in the New York Orthotec matter.
	Shareholder Note Receivable
	On March 15, 2014, the Company, Orthotec, LLC and certain other parties, including certain directors and affiliates of the Company, entered into the Binding Term Sheet to resolve the OrthoTec, LLC v. Surgiview, S.A.S., et al. matter in the Superior Court of California, Los Angeles County, and related matters. On September 26, 2014, the parties entered into the Settlement Agreement, which superceded the Binding Term Sheet (see Note 6 – Commitments and Contingencies – Litigation).  Pursuant to the Settlement Agreement, the Company agreed to pay Orthotec $49 million in cash, with initial cash payments of $1.75 million paid in March 2014 and $15.75 million paid in June 2014. The remaining $31.5 million will be paid to Orthotec in 28 quarterly installments of $1.1 million and then one additional quarterly installment of $0.7 million, commencing October 1, 2014. In June 2014, the Company and HealthpointCapital entered into an agreement for joint payment of settlement whereby HealthpointCapital has agreed to contribute $5 million to the $49 million settlement amount.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
In-Process Research and Development, Policy	'
	In-Process Research and Development
	In-process research and development (“IPR&D”) consists of acquired research and development assets that are not part of an acquisition of a business and were not technologically feasible on the date the Company acquired them and had no alternative future use at that date or IPR&D assets acquired in a business acquisition that are determined to have no alternative future use. The Company expects all acquired IPR&D will reach technological feasibility, but there can be no assurance that commercial viability of these products will ever be achieved. The nature of the efforts to develop the acquired technologies into commercially viable products consists principally of planning, designing, developing and testing products in order to obtain regulatory approvals. If commercial viability were not achieved, the Company would likely look to other alternatives to provide these products. Until the technological feasibility of the acquired research and development assets are established, the Company expenses these costs.
Fair Value Measurements	'
	Fair Value Measurements
	The carrying amount of financial instruments consisting of cash, restricted cash, trade accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses, accrued compensation and current portion of long-term debt included in the Company’s consolidated financial statements are reasonable estimates of fair value due to their short maturities. Based on the borrowing rates currently available to the Company for loans with similar terms, management believes the fair value of long-term debt approximates its carrying value.
	Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level 1:	Observable inputs such as quoted prices in active markets;
	Level 2:	Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3:	Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	The Company does not maintain any financial instruments that are considered to be Level 1 or Level 2 instruments as of September 30, 2014 or December 31, 2013. The Company classifies its common stock warrant liabilities within Level 3 of the fair value hierarchy because they are valued using valuation models with significant unobservable inputs.
Warrants to Purchase Common Stock	'
	Warrants to Purchase Common Stock
	Common stock warrants that contain compliance covenants and cash payment obligations are classified as common stock warrant liabilities on the consolidated balance sheet. The Company records the warrant liability at fair value and adjusts the carrying value of these common stock warrants to their estimated fair value at each reporting date with the increases or decreases in the fair value of such warrants at each reporting date recorded as other income (expense) in the consolidated statement of operations.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In March 2013, the Financial Accounting Standards Board (“FASB”) issued guidance on a parent company’s accounting for the cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. This new guidance requires that the parent release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. The amendments became effective for the Company beginning January 1, 2014. The Company adopted this guidance and the adoption did not have any impact on the Company's financial statements.
	In April 2014, the FASB issued new guidance related to reporting discontinued operations. This new standard raises the threshold for a disposal to qualify as a discontinued operation and requires new disclosures of both discontinued operations and certain other disposals that do not meet the definition of a discontinued operation. The new standard is effective for fiscal years beginning on or after December 15, 2014. The Company is evaluating the impact, if any, of adopting this new accounting standard on its financial statements.
	In May 2014, the FASB issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for the Company beginning January 1, 2017 and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is evaluating the impact of adopting this new accounting standard on its financial statements.
	In August 2014, the FASB issued guidance related to disclosures of uncertainties about an entity’s ability to continue as a going concern. The guidance requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued. Management will be required to make this evaluation for both annual and interim reporting periods and will have to make certain disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the entity’s ability to continue as a going concern. Substantial doubt exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued. The guidance is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter 2017, with early adoption permitted. The Company is currently evaluating the impact of this guidance and expects to adopt the standard for the annual reporting period ended December 31, 2016.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Reconciliation of liabilities measured at fair value using significant unobservable inputs	'
	The following table provides a reconciliation of liabilities measured at fair value using significant unobservable inputs (Level 3) for the nine months ended September 30, 2014 (in thousands):
		Common Stock Warrant Liabilities
	Balance at December 31, 2013	$	—
	Issuance	10,368
	Changes in fair value	292
	Balance at September 30, 2014	$	10,660
	Common stock warrant liabilities are measured at fair value using the Black-Scholes option pricing valuation model. The assumptions used in the Black-Scholes option pricing valuation model for the common stock warrant liabilities were: (a) a risk-free interest rate based on the rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the remaining contractual term of the warrants; (b) an assumed dividend yield of zero based on the Company’s expectation that it will not pay dividends in the foreseeable future; (c) an expected term based on the remaining contractual term of the warrants; and (d) an expected volatility based upon the Company's historical volatility over the remaining contractual term of the warrants. The significant unobservable input used in measuring the fair value of the common stock warrant liabilities associated with the Deerfield Facility Agreement (defined below) is the expected volatility. Significant increases in volatility would result in a higher fair value measurement. The increase in the fair value of the common stock warrant liabilities as of September 30, 2014 was primarily driven by the increase in the Company's stock price at September 30, 2014 as compared to the Company's stock price on March 17, 2014, the date the common stock warrants were issued.

Select_Balance_Sheet_Details_T

Select Balance Sheet Details (Tables)	9 Months Ended
	Sep. 30, 2014
Balance Sheet Related Disclosures [Abstract]	'
Accounts Receivable, net	'
	Accounts receivable, net consist of the following (in thousands):
		September 30, 2014				December 31, 2013
	Accounts receivable	$	41,062			$	42,443
	Allowance for doubtful accounts	(1,009		)		(1,048		)
	Accounts receivable, net	$	40,053			$	41,395
Inventories, net	'
	Inventories, net consist of the following (in thousands):
		September 30, 2014										December 31, 2013
		Gross				Reserve for				Net		Gross		Reserve for			Net
						excess and								excess and
						obsolete								obsolete
	Raw materials	$	4,526			$	—			$	4,526	$	4,375	$	—		$	4,375
	Work-in-process	1,017				—				1,017		531		—			531
	Finished goods	57,317				(20,874		)		36,443		60,979		(23,946		)	37,033
	Inventories	$	62,860			$	(20,874	)		$	41,986	$	65,885	$	(23,946	)	$	41,939
Property and Equipment, net	'
	Property and equipment, net consist of the following (in thousands except as indicated):
		Useful lives		September 30, 2014				December 31, 2013
		(in years)
	Surgical instruments	4		$	63,019			$	62,636
	Machinery and equipment	7		15,461				14,692
	Computer equipment	3		3,193				3,357
	Office furniture and equipment	5		3,823				3,703
	Leasehold improvements	various		3,719				4,161
	Building	39		72				52
	Land	n/a		10				10
	Construction in progress	n/a		1,016				1,228
				90,313				89,839
	Less accumulated depreciation and amortization			(63,803		)		(61,809		)
	Property and equipment, net			$	26,510			$	28,030
Intangible Assets, net	'
	Intangible assets, net consist of the following (in thousands except for useful lives):
		Useful lives		September 30, 2014				December 31, 2013
		(in years)
	Developed product technology	8-Mar		$	22,880			$	23,633
	Distribution rights	3		2,270				2,343
	Intellectual property	5		1,004				1,004
	License agreements	7-Jan		16,716				17,686
	Core technology	10		4,740				5,137
	Trademarks and trade names	9-Mar		3,674				3,920
	Customer-related	15-Dec		21,026				22,161
	Distribution network	12-Oct		4,027				4,027
	Physician education programs	10		2,916				3,160
	Supply agreement	10		225				225
				79,478				83,296
	Less accumulated amortization			(47,050		)		(44,232		)
	Intangible assets, net			$	32,428			$	39,064
Schedule of Intangible assets, future amortization expense	'
	Future amortization expense related to intangible assets as of September 30, 2014 is as follows (in thousands):
	Year Ending December 31,
	Remainder of 2014	$	1,493
	2015	5,792
	2016	5,281
	2017	4,984
	2018	3,127
	Thereafter	11,751
		$	32,428
Accrued Expenses	'
	Accrued expenses consist of the following (in thousands):
		September 30, 2014				December 31, 2013
	Legal	$	570			$	2,139
	Accounting	949				928
	Severance	459				297
	Restructuring	730				9,170
	Sales milestones	96				1,828
	Accrued taxes	811				1,120
	Deferred rent	884				1,163
	Royalties	2,443				2,347
	Commissions	5,275				6,180
	Payroll and related	8,013				9,369
	Litigation settlements	8,386				22,600
	Accrued interest	887				416
	Other	5,492				5,439
	Total accrued expenses	$	34,995			$	62,996
Schedule of changes in carrying amount of goodwill	'
	The changes in the carrying amount of goodwill from December 31, 2013 through September 30, 2014 are as follows (in thousands):
	Balance at December 31, 2013	$	183,004
	Effect of foreign exchange rate on goodwill	(7,915		)
	Balance at September 30, 2014	$	175,089

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Principal Payments on Debt	'
	Principal payments on debt are as follows as of September 30, 2014 (in thousands):
	Year Ending December 31,
	Remainder of 2014	$	2,018
	2015	6,869
	2016	54,894
	2017	6,667
	2018	6,667
	Thereafter	6,666
	Total	83,781
	Add: capital lease principal payments	1,491
	Less: debt discount	(6,613		)
	Total	78,659
	Less: current portion of long-term debt	(8,042		)
	Long-term debt, net of current portion	$	70,617

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Future Minimum Annual Lease Payments	'
	Future minimum annual lease payments under such leases are as follows as of September 30, 2014 (in thousands):
	Year Ending December 31,	Operating		Capital
	Remainder of 2014	$	877	$	181
	2015	3,228		662
	2016	1,827		623
	2017	377		183
	2018	68		—
	Thereafter	4		—
		$	6,381	1,649
	Less: amount representing interest			(158		)
	Present value of minimum lease payments			1,491
	Current portion of capital leases			(586		)
	Capital leases, less current portion			$	905

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Weighted Average Number of Common Shares Outstanding	'
	For purposes of this calculation, common stock subject to repurchase by the Company, options and warrants are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share when their effect is dilutive (in thousands, except per share data):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2014				2013			2014			2013
	Numerator:
	Net loss for basic earnings per share	$	(3,041	)		$	(14,510	)	$	(12,609	)	$	(21,820	)
	Decrease in fair value of warrants	(513		)		—			(520		)	—
	Diluted net loss applicable to common stockholders	$	(3,554	)		$	(14,510	)	$	(13,129	)	$	(21,820	)
	Denominator:
	Weighted average common shares outstanding	98,126				97,318			97,864			96,940
	Weighted average unvested common shares subject to repurchase	(735		)		(937		)	(824		)	(894		)
	Weighted average common shares outstanding—basic	97,391				96,381			97,040			96,046
	Effect of dilutive securities:
	Conversion of preferred stock	—				—			—			—
	Options	—				—			—			—
	Warrants	938				—			218			—
	Weighted average common shares outstanding—diluted	98,329				96,381			97,258			96,046
	Net loss per share:
	Basic	$	(0.03	)		$	(0.15	)	$	(0.13	)	$	(0.23	)
	Diluted	$	(0.04	)		$	(0.15	)	$	(0.13	)	$	(0.23	)
Weighted-Average Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share	'
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2014				2013			2014			2013
	Numerator:
	Net loss for basic earnings per share	$	(3,041	)		$	(14,510	)	$	(12,609	)	$	(21,820	)
	Decrease in fair value of warrants	(513		)		—			(520		)	—
	Diluted net loss applicable to common stockholders	$	(3,554	)		$	(14,510	)	$	(13,129	)	$	(21,820	)
	Denominator:
	Weighted average common shares outstanding	98,126				97,318			97,864			96,940
	Weighted average unvested common shares subject to repurchase	(735		)		(937		)	(824		)	(894		)
	Weighted average common shares outstanding—basic	97,391				96,381			97,040			96,046
	Effect of dilutive securities:
	Conversion of preferred stock	—				—			—			—
	Options	—				—			—			—
	Warrants	938				—			218			—
	Weighted average common shares outstanding—diluted	98,329				96,381			97,258			96,046
	Net loss per share:
	Basic	$	(0.03	)		$	(0.15	)	$	(0.13	)	$	(0.23	)
	Diluted	$	(0.04	)		$	(0.15	)	$	(0.13	)	$	(0.23	)
	The anti-dilutive securities not included in diluted net loss per share were as follows (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014		2013
	Options to purchase common stock	6,904			2,383			7,199		4,355
	Unvested restricted share awards	735			937			824		894
	Warrants to purchase common stock	594			594			6,844		594
	Total	8,233			3,914			14,867		5,843

Equity_Transactions_Tables

Equity Transactions (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Schedule of Assumptions Used	'
	At September 30, 2014, our outstanding warrants were valued using the Black-Scholes option pricing model. This is a Level 3 measurement using the following assumptions:
		September 30, 2014
	Risk-free interest rate	1.9	%
	Dividend yield	—	%
	Expected volatility	63	%
	Expected life (years)	5.5

Segment_and_Geographical_Infor1

Segment and Geographical Information (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Revenues Attributed to Geographic Location of Customer	'
	Revenues attributed to the geographic location of the customer were as follows (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	United States	$	34,808	$	33,696	$	101,376	$	99,249
	International	16,205		16,500		51,977		52,410
	Total consolidated revenues	$	51,013	$	50,196	$	153,353	$	151,659
Schedule of Long Lived Assets by Geographical Areas	'
	Total assets by region were as follows (in thousands):
		September 30,		December 31,
		2014		2013
	United States	$	200,012	$	196,383
	International	148,590		169,247
	Total consolidated assets	$	348,602	$	365,630

Restructuring_Tables

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
Schedule of Restructuring Reserve by Type of Cost	'
	Below is a table of the movement (in thousands):
		Accrued Balance at		Expensed		Paid and			Accrued Balance at		Total Costs
		31-Dec-13		September 30, 2014		Other			30-Sep-14		Incurred
	Social plan costs	$	9,170	$	197	$	(8,637	)	$	730	$	9,450
	Other restructuring costs	—		509		(509		)	—		921
	Total	$	9,170	$	706	$	(9,146	)	$	730	$	10,371

The_Company_and_Basis_of_Prese1

The Company and Basis of Presentation - Additional Information (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
	Market
Accounting Policies [Abstract]	'	'
Number of market for products	50	'
Cash	$20,169,000	$21,345,000
Anticipated cash flow from operations and other working capital, excluding common stock warrant liabilities	$37,000,000	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Accounting Policies [Abstract]	'	'	'	'
In-process research and development	$527	$0	$527	$0
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'	'	'
Balance at December 31, 2013	'	'	0	'
Issuance	'	'	10,368	'
Changes in fair value	'	'	292	'
Balance at September 30, 2014	$10,660	'	$10,660	'

Select_Balance_Sheet_Details_A

Select Balance Sheet Details - Accounts Receivable, Net (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'	'
Accounts receivable	$41,062	$42,443
Allowance for doubtful accounts	-1,009	-1,048
Accounts receivable, net	$40,053	$41,395

Select_Balance_Sheet_Details_I

Select Balance Sheet Details - Inventories, Net (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'	'
Raw materials, Gross	$4,526	$4,375
Work-in-process, Gross	1,017	531
Finished goods, Gross	57,317	60,979
Inventory, Gross, Total	62,860	65,885
Finished goods, Reserve for excess and obsolete	-20,874	-23,946
Inventories, net, Reserve for excess and obsolete	-20,874	-23,946
Raw materials, Net	4,526	4,375
Work-in-process, Net	1,017	531
Finished goods, Net	36,443	37,033
Inventories, Net	$41,986	$41,939

Select_Balance_Sheet_Details_P

Select Balance Sheet Details - Property and Equipment, Net (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and Equipment, Gross	$90,313,000	'	$90,313,000	'	$89,839,000
Less accumulated depreciation and amortization	-63,803,000	'	-63,803,000	'	-61,809,000
Property and Equipment, net	26,510,000	'	26,510,000	'	28,030,000
Depreciation	2,900,000	3,700,000	9,200,000	10,900,000	'
Surgical instruments [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Useful lives	'	'	'4 years	'	'
Property and Equipment, Gross	63,019,000	'	63,019,000	'	62,636,000
Machinery and equipment [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Useful lives	'	'	'7 years	'	'
Property and Equipment, Gross	15,461,000	'	15,461,000	'	14,692,000
Capital Leased Assets, Gross	3,200,000	'	3,200,000	'	1,800,000
Computer equipment [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Useful lives	'	'	'3 years	'	'
Property and Equipment, Gross	3,193,000	'	3,193,000	'	3,357,000
Office furniture and equipment [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Useful lives	'	'	'5 years	'	'
Property and Equipment, Gross	3,823,000	'	3,823,000	'	3,703,000
Leasehold improvements [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Various Useful lives of property and equipments	'	'	'various	'	'
Property and Equipment, Gross	3,719,000	'	3,719,000	'	4,161,000
Building [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Useful lives	'	'	'39 years	'	'
Property and Equipment, Gross	72,000	'	72,000	'	52,000
Land [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and Equipment, Gross	10,000	'	10,000	'	10,000
Construction in progress [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and Equipment, Gross	1,016,000	'	1,016,000	'	1,228,000
Capital Leased Assets, Gross	'	'	'	'	$600,000

Select_Balance_Sheet_Details_I1

Select Balance Sheet Details - Intangible Assets, Net (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Amortization	$1,600,000	$3,700,000	$4,800,000	$9,100,000	'
Intangible assets, Gross	79,478,000	'	79,478,000	'	83,296,000
Less accumulated amortization	-47,050,000	'	-47,050,000	'	-44,232,000
Intangible assets, net	32,428,000	'	32,428,000	'	39,064,000
Developed product technology [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Intangible assets, Gross	22,880,000	'	22,880,000	'	23,633,000
Developed product technology [Member] | Minimum [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Useful lives	'	'	'3 years	'	'
Developed product technology [Member] | Maximum [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Useful lives	'	'	'8 years	'	'
Distribution rights [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Useful lives	'	'	'3 years	'	'
Intangible assets, Gross	2,270,000	'	2,270,000	'	2,343,000
Intellectual property [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Useful lives	'	'	'5 years	'	'
Intangible assets, Gross	1,004,000	'	1,004,000	'	1,004,000
License agreements [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Intangible assets, Gross	16,716,000	'	16,716,000	'	17,686,000
License agreements [Member] | Minimum [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Useful lives	'	'	'1 year	'	'
License agreements [Member] | Maximum [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Useful lives	'	'	'7 years	'	'
Core technology [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Useful lives	'	'	'10 years	'	'
Intangible assets, Gross	4,740,000	'	4,740,000	'	5,137,000
Trademarks and trade names [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Intangible assets, Gross	3,674,000	'	3,674,000	'	3,920,000
Trademarks and trade names [Member] | Minimum [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Useful lives	'	'	'3 years	'	'
Trademarks and trade names [Member] | Maximum [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Useful lives	'	'	'9 years	'	'
Customer-related [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Intangible assets, Gross	21,026,000	'	21,026,000	'	22,161,000
Customer-related [Member] | Minimum [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Useful lives	'	'	'12 years	'	'
Customer-related [Member] | Maximum [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Useful lives	'	'	'15 years	'	'
Distribution network [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Intangible assets, Gross	4,027,000	'	4,027,000	'	4,027,000
Distribution network [Member] | Minimum [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Useful lives	'	'	'10 years	'	'
Distribution network [Member] | Maximum [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Useful lives	'	'	'12 years	'	'
Physician education programs [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Useful lives	'	'	'10 years	'	'
Intangible assets, Gross	2,916,000	'	2,916,000	'	3,160,000
Supply Agreement [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Useful lives	'	'	'10 years	'	'
Intangible assets, Gross	$225,000	'	$225,000	'	$225,000

Select_Balance_Sheet_Details_S

Select Balance Sheet Details - Schedule of Intangible assets, future amortization expense (Details) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'
Remainder of 2014	$1,493
2015	5,792
2016	5,281
2017	4,984
2018	3,127
Thereafter	11,751
Total	$32,428

Select_Balance_Sheet_Details_A1

Select Balance Sheet Details - Accrued Expense (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'	'
Legal	$570	$2,139
Accounting	949	928
Severance	459	297
Restructuring	730	9,170
Sales milestones	96	1,828
Accrued taxes	811	1,120
Deferred rent	884	1,163
Royalties	2,443	2,347
Commissions	5,275	6,180
Payroll and related	8,013	9,369
Litigation settlements	8,386	22,600
Accrued interest	887	416
Other	5,492	5,439
Total accrued expenses	$34,995	$62,996

Select_Balance_Sheet_Details_S1

Select Balance Sheet Details - Schedule of Changes in Carrying Amount of Goodwill (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Goodwill [Roll Forward]	'
Balance at December 31, 2013	$183,004
Effect of foreign exchange rate on goodwill	-7,915
Balance at September 30, 2014	$175,089

License_and_Consulting_Agreeme1

License and Consulting Agreements License and Consulting Agreements - Additional Information (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended		1 Months Ended	3 Months Ended	9 Months Ended
	Aug. 31, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Jul. 31, 2014	Sep. 30, 2014	Sep. 30, 2014
						Distribution Agreement with Parcell Spine, LLC [Member]	Distribution Agreement with Parcell Spine, LLC [Member]	Distribution Agreement with Parcell Spine, LLC [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'	'	'	'
Royalty rate	7.00%	'	'	'	'	'	'	'
Royalty rate, amended	8.50%	'	'	'	'	'	'	'
Royalty obligation per year	$200,000	'	'	'	'	'	'	'
Royalty accrual reversal	'	1,700,000	'	1,700,000	'	'	'	'
Payments to acquire in-process research and development	'	'	'	'	'	200,000	'	'
Stock issued during period, shares	'	'	'	'	'	72,992	'	'
Stock issued during period, value	'	'	'	'	'	100,000	'	'
In-process research and development	'	$527,000	$0	$527,000	$0	'	$300,000	$300,000

Debt_Additional_Information_De

Debt - Additional Information (Details) (USD $)

1 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

Feb. 28, 2013

Sep. 30, 2014

Sep. 30, 2013

Mar. 17, 2014

Dec. 31, 2013

Aug. 30, 2013

Sep. 30, 2013

Sep. 30, 2014

Jul. 30, 2013

Sep. 30, 2014

Aug. 30, 2013

Aug. 30, 2013

Sep. 30, 2014

Aug. 30, 2013

Mar. 20, 2014

Sep. 30, 2014

Mar. 17, 2014

Mar. 17, 2014

Apr. 10, 2014

Mar. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Oct. 01, 2014

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Deerfield [Member]

Deerfield [Member]

Deerfield [Member]

Maximum [Member]

Orthotec LLC, Litigation Settlement [Member]

Orthotec LLC, Litigation Settlement [Member]

Orthotec LLC, Litigation Settlement [Member]

Beginning October 2013 [Member]

Beginning October 2014 [Member]

Subsequent Event [Member]

Term Loan [Member]

Term Loan Drawn On Closing [Member]

Term Loan. Delayed Draw [Member]

Credit Facility [Member]

Credit Facility [Member]

payment

Deerfield [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Orthotec LLC, Litigation Settlement [Member]

Line of Credit Facility [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

'

$73,000,000

'

'

$50,000,000

'

$33,000,000

$5,000,000

'

$40,000,000

'

'

$50,000,000

'

'

'

'

'

'

'

Repayments of Lines of Credit

'

115,068,000

130,017,000

'

'

28,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate description

'

'

'

'

'

'

'

'

'

'( "LIBOR") plus 8.0%

'

'

'LIBOR plus 6.0%

'

'

'

'

'

'

'

'

'

'

'

Debt, spread on variable rate

'

'

'

'

'

'

'

'

'

8.00%

'

'

6.00%

'

'

'

'

'

'

'

'

'

'

'

Floor on interest rate

'

'

'

'

'

'

'

'

'

9.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate of revolving line of credit

'

'

'

'

'

'

'

'

'

9.50%

'

'

6.20%

'

'

'

'

'

'

'

'

'

'

'

Term loan payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

500,000

'

Unamortized debt issuance and debt discount costs

'

6,613,000

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt issuance costs

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional interest rate to be charged in the event of default

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amendment fee

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate amount of draw down for working capital

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000,000

'

'

'

'

'

'

'

Increment amount of draw down for general corporate purposes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

'

'

'

'

Transaction fee as percentage of principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.50%

'

'

'

'

'

'

'

Debt instrument, stated interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.75%

'

'

'

'

'

'

'

Number of securities called by warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,250,000

'

'

'

'

'

'

'

Number of securities called by warrants associated with each disbursement borrowing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

Amount of initial draw-down under Facility Agreement

'

'

'

'

'

'

'

'

'

'

'

'

31,800,000

'

20,000,000

'

'

'

'

'

'

'

'

'

Net Proceeds from Initial Draw Under Facility Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19,500,000

'

'

'

'

'

'

'

'

'

Transaction fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

Number of warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

'

'

'

Warrants value

'

'

'

5,700,000

'

'

'

'

'

'

'

'

'

'

4,700,000

'

'

'

'

'

'

'

'

'

Warrant amount reclassified as debt discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,300,000

'

'

'

'

'

'

'

'

'

Litigation settlement expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,750,000

1,750,000

17,500,000

'

'

1,100,000

Restricted cash

'

$2,001,000

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Equal Annual Payments to Make Under Facility Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

Debt_Principal_Payments_on_Deb

Debt - Principal Payments on Debt (Details) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]	'
Remainder of 2014	$2,018
2015	6,869
2016	54,894
2017	6,667
2018	6,667
Thereafter	6,666
Total	83,781
Add: capital lease principal payments	1,491
Less: debt discount	-6,613
Total	78,659
Less: current portion of long-term debt	-8,042
Long-term debt, net of current portion	$70,617

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Details) (USD $)

3 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Apr. 10, 2014

Mar. 15, 2014

Mar. 31, 2014

Sep. 30, 2014

Mar. 15, 2014

Mar. 15, 2014

Mar. 15, 2014

Jan. 08, 2014

Minimum [Member]

Maximum [Member]

Orthotec LLC, Litigation Settlement [Member]

Orthotec LLC, Litigation Settlement [Member]

Orthotec LLC, Litigation Settlement [Member]

Orthotec LLC, Litigation Settlement [Member]

Orthotec LLC, Litigation Settlement [Member]

Beginning Fourth Quarter of 2014 [Member]

Final Installment [Domain]

Healthpoint Capital [Member]

Healthpoint Capital [Member]

Orthotec LLC, Litigation Settlement [Member]

Orthotec LLC, Litigation Settlement [Member]

Loss Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital leases expire date

'

'

30-Jun-17

'

'

'

'

'

'

'

'

'

'

'

Lease interest rate

'

'

'

'

6.60%

9.60%

'

'

'

'

'

'

'

'

Rent expense

$800,000

$900,000

$2,600,000

$2,900,000

'

'

'

'

'

'

'

'

'

'

Judgment assessed by court

'

'

'

'

'

'

'

49,000,000

'

'

'

31,500,000

'

'

Litigation settlement expense

'

'

'

'

'

'

15,750,000

'

1,750,000

17,500,000

'

'

'

'

Litigation settlement, quarterly installments, amount

'

'

'

'

'

'

'

'

'

'

'

1,100,000

'

'

Litigation Settlement, Final Installment, Amount

'

'

'

'

'

'

'

'

'

'

'

'

700,000

'

Litigation settlement, contribution by entity involved, amount

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

Litigation settlement interest rate

'

'

'

'

'

'

'

'

'

'

'

7.00%

'

'

Litigation settlement interest, quarterly installments, amount

'

'

'

'

'

'

'

1,100,000

'

'

'

'

'

'

Attorneys' fees paid by insurance carriers

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,250,000

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Annual Lease Payments (Details) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Leases [Abstract]	'
Operating leases Remainder of 2014	$877
Operating leases 2015	3,228
Operating leases 2016	1,827
Operating leases 2017	377
Operating leases 2018	68
Operating leases Thereafter	4
Operating leases, Future Minimum Payments Due, Total	6,381
Capital leases Remainder of 2014	181
Capital leases 2015	662
Capital leases 2016	623
Capital leases 2017	183
Capital leases 2018	0
Capital leases Thereafter	0
Total Capital leases	1,649
Less: amount representing interest	-158
Present value of minimum lease payments	1,491
Current portion of capital leases	-586
Capital leases, less current portion	$905

Net_Loss_Per_Share_Weighted_Av

Net Loss Per Share - Weighted Average Number of Common Shares Outstanding (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Numerator:	'	'	'	'
Net loss for basic earnings per share	($3,041)	($14,510)	($12,609)	($21,820)
Decrease in fair value of warrants	-513	0	-520	0
Diluted net loss applicable to common stockholders	($3,554)	($14,510)	($13,129)	($21,820)
Denominator:	'	'	'	'
Weighted average common shares outstanding	98,126	97,318	97,864	96,940
Weighted average unvested common shares subject to repurchase	-735	-937	-824	-894
Weighted average common shares outstanding—basic	97,391	96,381	97,040	96,046
Effect of dilutive securities:	'	'	'	'
Warrants	938	0	218	0
Weighted average common shares outstanding—diluted	98,329	96,381	97,258	96,046
Net loss per share:	'	'	'	'
Basic	($0.03)	($0.15)	($0.13)	($0.23)
Diluted	($0.04)	($0.15)	($0.13)	($0.23)

Net_Loss_Per_Share_WeightedAve

Net Loss Per Share - Weighted-Average Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share (Details)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities not included in diluted net loss per share	8,233	3,914	14,867	5,843
Options to purchase common stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities not included in diluted net loss per share	6,904	2,383	7,199	4,355
Unvested restricted share awards [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities not included in diluted net loss per share	735	937	824	894
Warrants to purchase common stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities not included in diluted net loss per share	594	594	6,844	594

Equity_Transactions_Additional

Equity Transactions - Additional Information (Details) (USD $)	3 Months Ended		9 Months Ended				0 Months Ended		3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Mar. 17, 2014	Dec. 31, 2013	Mar. 20, 2014	Mar. 17, 2014	Sep. 30, 2014	Sep. 30, 2014	Mar. 17, 2014
							Deerfield [Member]	Deerfield [Member]	Deerfield [Member]	Deerfield [Member]	Maximum [Member]
											Deerfield [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Number of securities called by warrants	'	'	'	'	'	'	'	6,250,000	'	'	'
Exercise price of warrants	'	'	'	'	'	'	1.39	1.39	'	'	'
Number of securities called by warrants associated with each disbursement borrowing	'	'	'	'	'	'	'	'	'	'	10,000,000
Number of days following borrowing request to determine exercise price associated with each disbursement borrowing under facility agreement	'	'	'	'	'	'	'	'15 days	'	'	'
Maximum borrowing capacity	'	'	'	'	'	'	'	$50,000,000	'	'	'
Warrants value	'	'	'	'	5,700,000	'	4,700,000	'	'	'	'
Amount of initial draw-down under Facility Agreement	'	'	'	'	'	'	20,000,000	'	'	'	'
Net Proceeds from Initial Draw Under Facility Agreement	'	'	'	'	'	'	19,500,000	'	'	'	'
Number of warrants issued	'	'	'	'	'	'	4,000,000	'	'	'	'
Warrant amount reclassified as debt discount	'	'	'	'	'	'	2,300,000	'	'	'	'
Warrants issued and outstanding	'	'	'	'	'	'	'	'	10,250,000	10,250,000	'
Other income (expense)	-928,000	210,000	-1,230,000	-840,000	'	'	'	'	500,000	300,000	'
Common stock warrant liabilities	$10,660,000	'	$10,660,000	'	'	$0	'	'	'	'	'
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Risk-free interest rate	1.90%	'	'	'	'	'	'	'	'	'	'
Dividend yield	0.00%	'	'	'	'	'	'	'	'	'	'
Expected volatility	63.00%	'	'	'	'	'	'	'	'	'	'
Expected life (years)	'5 years 6 months	'	'	'	'	'	'	'	'	'	'

Stock_Benefit_Plans_and_StockB1

Stock Benefit Plans and Stock-Based Compensation (Details) (2005 Employee, Director and Consultant Stock Plan [Member], Performance-based Restricted Stock Units [Member], USD $)	1 Months Ended
	Jul. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Non-Option equity instruments, granted shares	932,000
Non-option equity instruments, grant date fair value	$1.42
Minimum [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Award vesting percentage	0.00%
Maximum [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Award vesting percentage	200.00%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Unrecognized tax benefits increase	$0.10
Unrecognized tax benefits	$7.80

Segment_and_Geographical_Infor2

Segment and Geographical Information - Additional Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
	Location	Location	Segment	Location
			Location
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Number of operating segments	'	'	1	'
Number of reportable business segment	'	'	1	'
Number of geographic regions	2	2	2	2
Revenue	$51,013	$50,196	$153,353	$151,659
Minimum percentage of revenues	'	'	'	10.00%
Japan [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenue	$8,500	$7,300	$23,800	$20,800
Minimum percentage of revenues	'	'	10.00%	'

Segment_and_Geographical_Infor3

Segment and Geographical Information - Schedule of Revenues Attributed to Geographic Location of Customer (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Total consolidated revenues	$51,013	$50,196	$153,353	$151,659
Japan [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Total consolidated revenues	8,500	7,300	23,800	20,800
Reportable Geographical Components [Member] | United States [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Total consolidated revenues	34,808	33,696	101,376	99,249
Reportable Geographical Components [Member] | International [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Total consolidated revenues	$16,205	$16,500	$51,977	$52,410

Segment_and_Geographical_Infor4

Segment and Geographical Information - Schedule of Long Lived Assets by Geographical Areas (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total consolidated assets	$348,602	$365,630
Reportable Geographical Components [Member] | United States [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total consolidated assets	200,012	196,383
Reportable Geographical Components [Member] | International [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total consolidated assets	$148,590	$169,247

Restructuring_Additional_Infor

Restructuring - Additional Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Total Costs Incurred	'	'	$10,371	$10,400	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'
Accrued Balance at December 31, 2013	'	'	9,170	'	'
Expensed	20	4,045	706	'	4,045
Paid and Other	'	'	-9,146	'	'
Accrued Balance at June 30, 2014	730	'	730	'	'
Social Plan [Member]	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Total Costs Incurred	'	'	9,450	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'
Accrued Balance at December 31, 2013	'	'	9,170	'	'
Expensed	'	'	197	'	'
Paid and Other	'	'	-8,637	'	'
Accrued Balance at June 30, 2014	730	'	730	'	'
Other Restructuring [Member]	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Total Costs Incurred	'	'	921	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'
Accrued Balance at December 31, 2013	'	'	0	'	'
Expensed	'	'	509	'	'
Paid and Other	'	'	-509	'	'
Accrued Balance at June 30, 2014	$0	'	$0	'	'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Details) (USD $)	9 Months Ended			0 Months Ended		1 Months Ended	9 Months Ended	0 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Apr. 10, 2014	Mar. 15, 2014	Mar. 31, 2014	Sep. 30, 2014	Mar. 15, 2014	Mar. 15, 2014
	Healthpoint Capital [Member]	New York Orthotec matter [Member]	New York Orthotec matter [Member]	Orthotec LLC, Litigation Settlement [Member]	Orthotec LLC, Litigation Settlement [Member]	Orthotec LLC, Litigation Settlement [Member]	Orthotec LLC, Litigation Settlement [Member]	Beginning Fourth Quarter of 2014 [Member]	Healthpoint Capital [Member]
								Orthotec LLC, Litigation Settlement [Member]	Orthotec LLC, Litigation Settlement [Member]
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'
Incurred expenses	$0.20	'	'	'	'	'	'	'	'
Payable liability	0.2	'	'	'	'	'	'	'	'
Legal expenses	'	0.1	1.3	'	'	'	'	'	'
Litigation settlement amount	'	'	'	'	49	'	'	31.5	'
Litigation settlement expense	'	'	'	15.75	'	1.75	17.5	'	'
Litigation settlement, quarterly installments, amount	'	'	'	'	'	'	'	1.1	'
Litigation settlement, contribution by entity involved, amount	'	'	'	'	'	'	'	'	$5